CORRECTED - CORRECTED-BEFORE THE BELL-Avanir rises after Zenvia data

(Corrects typo in headline)

NEW YORK, Nov 10 (Reuters) - Shares of Avanir Pharmaceuticals Inc (AVNR.O) rose 10 percent to $2.05 in premarket trading on Tuesday after the company announced safety and efficacy data from a trial of its Zenvia product.

For details, see [ID:nWNAB3702]

(Reporting by Ryan Vlastelica)